Trial Profile
Development of Second Primary Malignancy after Treatment with Lenalidomide to establish the real-world of second primary malignancy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association